Core Viewpoint - Fosun International's chairman Guo Guangchang stated that the RMB 23.4 billion impairment provision is a "prudent accounting treatment" and not indicative of operational issues, marking a new development phase for the company [1][2] Group 1: Financial Performance - For the reporting period, Fosun's total revenue reached RMB 173.43 billion, with adjusted operating profit at RMB 4 billion [2] - The four core subsidiaries generated revenue of RMB 128.2 billion, accounting for 74% of the total revenue [2] - Fosun Pharma reported a net profit of RMB 3.371 billion, a year-on-year increase of 21.69%, while Fosun Portugal Insurance achieved a net profit of EUR 201 million, up 15.8% [2] Group 2: Impairment and Strategic Focus - The company conducted a one-time non-cash impairment provision and value reassessment for certain real estate projects and non-core business segments, resulting in an annual loss of RMB 23.4 billion, with 55% attributed to real estate impairment and 45% to non-core asset impairment [2] - Guo emphasized the company's commitment to exiting underperforming assets and focusing resources on high-growth core sectors to promote a more sustainable and healthier development [1][2] Group 3: Future Outlook and Shareholder Returns - The adjusted net asset value (NAV) of Fosun is RMB 133.5 billion, with a per-share NAV of HKD 18.1 [2] - The board has announced a share buyback plan, and major shareholders and management will increase their holdings [2] - Fosun plans to explore and gradually implement more shareholder return measures, including optimizing the dividend mechanism, based on operational improvements and cash flow [2]